
With the Dividend Data connector, your AI app answers from the same data as this page and links the page behind each number. A free Dividend Data account connects.
Questions to try
The Amplify Digital Payments ETF, identified by its ticker IPAY, is designed to replicate the total return performance of the Nasdaq CTA Global Digital Payments Index, before accounting for its own fees and expenses. This fund provides investors with exposure to a global portfolio of companies that are integral to the digital payment ecosystem, encompassing areas such as card networks, payment infrastructure and software development, transaction processing, and various related financial technology solutions.
Is IPAY's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Pro · $599/yr ($49/mo) · 30-day money-back guarantee

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026. "Based on our analysis of CMS's final rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.

Stripe and Advent have made a $53B bid for PayPal, lifting PYPL shares and putting fintech ETFs like PYPU, FINX and IPAY in the spotlight.

SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on June 12, 2026. "Based on our analysis of CMS's proposed rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.

Amplify Digital Payments ETF is downgraded to Hold due to unresolved structural and idiosyncratic risks impacting major holdings. AI-driven transaction rerouting and stablecoin adoption now pose significant threats to traditional payment networks, justifying a valuation discount to the S&P 500. IPAY's top holdings, including PayPal and Fiserv, suffered operational setbacks and earnings disappointments, driving underperformance and heightened volatility.

Amplify Digital Payments ETF (NYSEARCA:IPAY - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 37,045 shares, a growth of 32.5% from the December 31st total of 27,952 shares. Based on an average daily volume of 32,552